

Stephanie De Bono

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11130525/publications.pdf>

Version: 2024-02-01

28
papers

5,170
citations

361413

20
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

6186
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 327-336.	10.7	131
2	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2022, 24, 112.	3.5	19
3	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 888-899.	10.7	62
4	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 795-807.	27.0	1,398
5	Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 107-111.	2.9	140
6	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1407-1418.	10.7	501
7	Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). <i>Trials</i> , 2021, 22, 689.	1.6	26
8	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020, 7, e000424.	2.7	35
9	Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. <i>EMBO Molecular Medicine</i> , 2020, 12, e12697.	6.9	229
10	Baricitinib for systemic lupus erythematosus – Authors' reply. <i>Lancet</i> , 2019, 393, 402-403.	13.7	5
11	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 890-898.	0.9	22
12	Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. <i>Trials</i> , 2019, 20, 182.	1.6	31
13	199...Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. , 2019, , .		2
14	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 988-995.	0.9	41
15	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2018, 4, e000662.	3.8	18
16	Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1923-1932.	5.6	26
17	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2018, 392, 222-231.	13.7	396
18	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 652-662.	27.0	643

#	ARTICLE	IF	CITATIONS
19	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000410.	3.8	28
20	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 88-95.	0.9	295
21	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1853-1861.	0.9	83
22	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease—Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 506-517.	5.6	310
23	Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 237.	2.4	1
24	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252.	27.0	499
25	Birth weight predicts bone size in young adulthood at cortical sites in men and trabecular sites in women from The Gambia. <i>Bone</i> , 2010, 46, 1316-1321.	2.9	18
26	Symposium on “Nutrition and health in children and adolescents”™ Session 1: Nutrition in growth and development Nutrition and bone growth and development. <i>Proceedings of the Nutrition Society</i> , 2006, 65, 348-360.	1.0	129
27	A segment of cold shock protein directs the folding of a combinatorial protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 1396-1401.	7.1	31
28	Folding and Stability of a Primitive Protein. <i>Journal of Molecular Biology</i> , 2005, 348, 1261-1272.	4.2	16